Ipilimumab in Extensive Stage Small Cell Lung Cancer
|Drug class||Target||Agent||Diseases||Line of Therapy||Status||Source|
|CTLA-4 inhibitors, Immunotherapy, Monoclonal antibody||CTLA-4||ipilimumab (Yervoy)||small cell lung cancer||metastatic||Trials complete with results||Reck et al. 2013; Antonia et al. 2015|
The efficacy and safety of CTLA-4 inhibitors for the treatment of patients with small cell lung cancer (SCLC) is currently under investigation. Ipilimumab has shown potential in treating patients with extensive SCLC in a phase II trial (NCT00527735; Reck et al. 2013).
In a phase I/II study comparing treatment with nivolumab alone andversus nivolumab in combination with ipilimumab in patients with recurrent SCLC, the combination arm demonstrated higher response rates than the single agent arm (CA209-032; Antonia et al. 2015).
|Reference||Study Type / Phase||Line of Treatment||Treatment Agent||# Patients in Study||Response Rate||PFS (months)||OS (months)|
|Reck et al. 2013||Phase II||1st line||concurrent ipilimumab + carboplatin + paclitaxel||43||33%||3.9||9.1|
|phased ipilimumab + carboplatin + paclitaxel||42||57%||5.2||12.5|
|carboplatin + paclitaxel||45||49%||5.2||10.5|
|Antonia et al. 2015 (CA209-032)||Phase I/II||2nd line||nivolumab||40||15%|
|nivolumab + ipilimumab||35||25%|
Suggested Citation: Iams, W.T., D. Johnson, C. Lovly. 2015. Immunotherapy in Cancer. My Cancer Genome http://www.padiracinnovation.org/content/molecular-medicine/c2654-small-cell-lung-cancer/ (Updated September 3).
Last Updated: September 24, 2015